Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation

Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1) pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual disease (MRD) by molecular and immunophenotyping criteria. We assessed interactions of MRD status with HCT conditioning regi...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2018-09, Vol.93 (9), p.1142-1152
Main Authors: Gilleece, Maria H., Labopin, Myriam, Yakoub‐Agha, Ibrahim, Volin, Liisa, Socié, Gerard, Ljungman, Per, Huynh, Anne, Deconinck, Eric, Wu, Depei, Bourhis, Jean Henri, Cahn, Jean Yves, Polge, Emmanuelle, Mohty, Mohamad, Savani, Bipin N., Nagler, Arnon
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Graft-versus-host reaction
Hematology
Leukemia
Life Sciences
Medicin och hälsovetenskap
Multivariate analysis
Myeloid leukemia
Remission
Stem cell transplantation
Toxicity
Transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1) pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual disease (MRD) by molecular and immunophenotyping criteria. We assessed interactions of MRD status with HCT conditioning regimen intensity in patients aged 18y with AML CR1 MRD NEG/POS and recipients of HCT in 2000‐2015. Conditioning regimens were myeloablative (MAC), reduced intensity (RIC) or non‐myeloablative (NMA). Outcomes included leukemia free survival (LFS), overall survival (OS), relapse incidence (RI), non‐relapse mortality (NRM), chronic graft‐vs‐host (cGVHD), and GVHD‐free and relapse‐free survival (GRFS). The 2292 eligible patients were categorized into four paired groups:
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.25211